Testosterone cypionate 250mg/ml - Testo Cy BD 10ml
Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. The characteristics of testosterone cypionate and testosterone enanthate are very similar, therefore both of them tend to be interchangeable.6 It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.
Available In Stock
Buy Testosterone cypionate 250mg/ml Online | Injectable Steroids Testo Cy BD 10ml Vial for Sale | Thailand Steroids for Sale | Get Better Price for Bulk Orders - Contact Whatsapp
Testosterone cypionate, what is it indicated for and what is it for?
Testosterone cypionate is indicated for men in testosterone replacement therapy in cases of primary or secondary male hypogonadism .
What are the contraindications for Testosterone Cypionate?
Testosterone cypionate is contraindicated in the following conditions:
Hypersensitivity to any component of the formulation;
Androgen-dependent carcinoma of the prostate or mammary gland of man;
Heart , liver or kidney failure.
The use of Testosterone Cypionate is contraindicated in women and children.
This medicine is contraindicated for use by women.
This medicine is contraindicated for children or adolescents under the age of 18 years.
This medicine is contraindicated for use by women who are pregnant or who may become pregnant during treatment.
How to use Testosterone Cypionate?
Testosterone cypionate should only be administered intramuscularly. It must be applied deeply to the gluteal muscle. The application must be done slowly.
The use of a wet needle or syringe can cause turbidity in the solution, which does not, however, affect the effectiveness of the medication.
If crystals form in the ampoules, heating and stirring can provide immediate redissolution.
The presence of foreign particles in the solution should be checked before administration.
Shake well before use.
Testosterone cypionate should be applied deeply and slowly intramuscularly to the gluteal muscle.
Replacement therapy should be instituted with the administration of 200 mg of testosterone cypionate every 2 weeks, capable of maintaining sufficient testosterone levels without leading to accumulation.
It is advisable to measure serum testosterone levels at the end of an interval between administrations. Serum levels below the values considered normal indicate the need for a shorter interval between injections. In case of high serum levels, an increase in the interval between the administration of two injections should be considered.
What are the adverse reactions and side effects of Testosterone Cypionate?
The following adverse reactions may occur with the use of androgens:
Endocrine and urological system: gynecomastia and increased frequency of erections. Oligospermia can occur with the use of high doses;
Skin and attachments: skin changes, hirsutism, alopecia , seborrhea and acne ;
Metabolic system: retention of sodium, chloride, water, potassium, calcium and inorganic phosphates;
Gastrointestinal system: nausea, cholestatic jaundice , abnormal values in liver laboratory tests, rarely liver neoplasms and pelitis hepatitis ;
Blood and lymphatic system: bleeding in patients being treated with oral anticoagulants and polycythemia;
Nervous system: increase or decrease in libido, headache , anxiety , depression and generalized paresthesia ;
General: inflammation and pain at the site of intramuscular administration.
Treatment with high-dose testosterone drugs commonly interrupts or reduces spermatogenesis, which also reduces the size of the testicles.
In case of adverse events, notify the Health Surveillance Notification System - NOTIVISA, available at http://www.anvisa.gov.br/hotsite/notivisa/index.htm, or to the State or Municipal Health Surveillance.
Drug interaction: what are the effects of taking Testosterone Cypionate with other medications?
An adjustment in the dosage of oral anticoagulants may be necessary, since there are reports in the literature that testosterone and its derivatives increase the activity of these agents. Regardless of this finding and as a general rule, limitations on the use of intramuscular injections in patients with acquired or hereditary abnormalities of blood coagulation should always be observed.
Concomitant administration with androgens may result in an increase in serum oxyphenbutazone levels.
Androgens can intensify the hypoglycemic effects of insulin causing a decrease in blood glucose levels. Therefore, a reduction in the dosage of the hypoglycemic agent may be necessary.
What precautions should I take when using Testosterone Cypionate?
Hypercalcemia can occur in immobilized patients. In that case, treatment should be stopped.
The prolonged use of high doses of androgens (mainly 17-alpha-alkyl androgens) has been associated with the development of liver adenomas, hepatocellular carcinoma and peliosis hepatitis.
Caution should be exercised in patients predisposed to edema. Edema, with or without congestive heart failure, can cause serious complications in patients with pre-existing heart, kidney or liver disease.
Treatment patients can develop gynecomastia.
The use of androgens is not recommended to improve athletic performance. Due to the potential risks of serious adverse events, Testosterone Cypionate should not be used for this purpose.
Patients with benign prostatic hypertrophy can develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Prolonged use or excessive dosages of testosterone cypionate can lead to the appearance of oligospermia. In case of the appearance of some of the effects mentioned above, the treatment should be interrupted and started with a lower dosage.
Testosterone cypionate should not be used intravenously.
Like all oily solutions, Testosterone Cypionate should be administered intramuscularly. Short-term reactions (need to cough, coughing , breathing difficulties) that occur in isolated cases during or immediately after parenteral administration of oily solutions can be proven to be avoided by administering the drug extremely slowly.
Testosterone has been tested in mice and rats through subcutaneous implantation. The implant induces the appearance of a cervical-uterine tumor in mice. There is no evidence that parenteral administration of testosterone in some strains of mice increases their susceptibility to hepatoma. Testosterone can also increase the number of tumors and decrease the degree of chemical differentiation of liver carcinoma in rats.
There are no reports of hepatocellular carcinoma in patients undergoing long-term androgenic treatment.
Teratogenic effects. This medicine should not be used by women who are pregnant or who may become pregnant during treatment.
The use of testosterone cypionate is not recommended during lactation.
Elderly, children and other risk groups
Elderly patients treated with androgens may be at increased risk of developing prostatic hyperplasia and prostatic carcinoma, although there is no conclusive clinical evidence. For this reason, prostate and blood tests are often performed before prescribing androgens for men over 40.
Tests should be repeated during treatment.
There are no data from clinical trials to support the use of Testosterone Cypionate in children and adolescents under 18 years of age. In children, testosterone, in addition to causing masculinization, can accelerate bone growth and maturation, and cause premature closure of the epiphyses, which reduces the final height.
What does Testosterone Cypionate do?
Male hypogonadism is one of the most common endocrinological syndromes. Available literature data that the intramuscular administration of oil-based testosterone cypionate are widely used in the treatment of male hypogonadism. Androgen replacement therapy is used to induce and maintain normal secondary sexual characteristics.
Darby, E .; Anawalt, BD Male Hypogonadism - An Update on Diagnosis and Treatment. Treat Endocrinol, 2005. Matsumoto, AM Hormonal terapy of Male Hypogonadism. Clinical Andrology, 1994.
Testosterone cypionate is an injectable solution for intramuscular use that contains testosterone cypionate in its formulation.
Testosterone cypionate is an oil-based injectable solution, thus allowing a prolonged release of testosterone, and the ester base, which allows rapid release of free testosterone into the circulation.
Testosterone, the main natural androgen, is responsible for the growth and development of male sexual organs and the maintenance of secondary sexual characters. These effects include the growth and maturation of the prostate, seminal vesicles, penis and scrotum; development and distribution of hair, such as beard, pubis, chest and axillary hair; enlargement of the larynx and thickening of the vocal cords; changes in muscle mass and distribution of body fat.
Testosterone is the most important androgenic steroid hormone in males produced in the testicles and adrenal cortex.
Insufficient testosterone secretion results in male hypogonadism characterized by low serum testosterone concentrations. Symptoms associated with male hypogonadism include, among others, impotence and decreased libido, fatigue , depression, as well as, incomplete development or absence or regression of male sexual characteristics.
Exogenous androgen administration improves deficient levels of endogenous testosterone and symptoms related to hypogonadism.
Testosterone esters are less polar than free testosterone, so they are absorbed more slowly when administered intramuscularly in an oily vehicle, thus prolonging the time between doses. Therefore, Testosterone Cypionate should be administered at intervals of two to four weeks.
Approximately 98% of circulating serum testosterone is bound to testosterone-estradiol-binding or sex hormone-binding globulin (SHBG). About 2% is in free form.
Generally, the amount of this sex hormone bound to globulin in the plasma will determine the distribution of testosterone between the free and the conjugate fraction. The fraction of free testosterone will determine its half-life.
The half-life of testosterone cypionate when administered intramuscularly is about eight days.
A small percentage of testosterone is converted to biologically active metabolites in certain tissues; however, most are converted to inactive metabolites, excreted through the kidneys and bile ducts.
Testosterone inactivation occurs predominantly in the liver.
About 90% of testosterone is eliminated in the urine in the form of conjugates of glucuronic acid and testosterone sulfuric acid and its metabolites. About 6% is excreted in the faeces, mainly in the